Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer.

Nucera says in the past year, it was discovered that less than 2% of the human genome is encoded for protein. This means that the noncoding region transcribes the majority of the genome.

As a new field, physicians are investigating the role of RNA in thyroid cancer. Nucera says he is attempting to discover the regulatory effect of noncoding RNA in thyroid cancer. There is also suspicion that BRAFV600E interplays with the RNA.

View more from the 2014 ATA Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Annual Meeting of the American Thyroid Association

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Dr. Nucera Discusses the Role of RNA in Thyroid Cancer